Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. ACADIA Pharmaceuticals's selling, general, & admin. expense for the
three
months ended in Mar. 2026 was MXN3,084 Mil.
Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Mar. 2026 was MXN10,847 Mil.
ACADIA Pharmaceuticals (MEX:ACAD) Selling, General, & Admin. Expense Explanation
An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.
Warren Buffett likes companies with consistent SGA as the percentage of gross profit.
Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.
If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.
ACADIA Pharmaceuticals Selling, General, & Admin. Expense Related Terms
ACADIA Pharmaceuticals Selling, General, & Admin. Expense Historical Data
* Premium members only.
The historical data trend for ACADIA Pharmaceuticals's Selling, General, & Admin. Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACADIA Pharmaceuticals Selling, General, & Admin. Expense Chart
MEX:ACAD vs VKTX, EWTX, DNLI: Selling, General, & Admin. Expense Comparison
For the Biotechnology subindustry, ACADIA Pharmaceuticals's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ACADIA Pharmaceuticals Selling, General, & Admin. Expense vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's Selling, General, & Admin. Expense distribution charts can be found below:
* The bar in red indicates where ACADIA Pharmaceuticals's Selling, General, & Admin. Expense falls into.
ACADIA Pharmaceuticals Selling, General, & Admin. Expense Calculation
Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.
Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN10,847 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Selling, General, & Admin. Expense of MXN10,847 Mil mean?
ACADIA Pharmaceuticals (MEX:ACAD) has a Selling, General, & Admin. Expense of MXN10,847 Mil as of Mar. 2026. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on ACADIA Pharmaceuticals and its competitors.
Is ACADIA Pharmaceuticals' Selling, General, & Admin. Expense too high?
ACADIA Pharmaceuticals' current Selling, General, & Admin. Expense is MXN10,847 Mil. Overall, ACADIA Pharmaceuticals has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ACADIA Pharmaceuticals' Selling, General, & Admin. Expense compare to VKTX and EWTX?
ACADIA Pharmaceuticals' Selling, General, & Admin. Expense of MXN10,847 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Biotechnology company?
A good Selling, General, & Admin. Expense depends on the Biotechnology industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on ACADIA Pharmaceuticals and its competitors. ACADIA Pharmaceuticals's current Selling, General, & Admin. Expense is MXN10,847 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACADIA Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals (MEX:ACAD) is currently considered Fairly Valued. The stock's GF Value™ is MXN442.11, compared to a current price of MXN453.75 — trading 2.6% above its estimated fair value. The current Selling, General, & Admin. Expense is MXN10,847 Mil. ACADIA Pharmaceuticals' overall GF Score™ is 73/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For ACADIA Pharmaceuticals (MEX:ACAD), the current Selling, General, & Admin. Expense is MXN10,847 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACADIA Pharmaceuticals (MEX:ACAD) Overvalued in 2026?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be overvalued.
The current stock price of MXN453.75 is trading 2.6% above its estimated GF Value™ of MXN442.11.
GuruFocus considers ACADIA Pharmaceuticals to be Fairly Valued.
Key valuation signals for MEX:ACAD:
Selling, General, & Admin. Expense: MXN10,847 Mil
GF Value™: MXN442.11 vs. price of MXN453.75 (2.6% above fair value)
No single metric tells the full story. See the MEX:ACAD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
73GF Score
Get the complete analysis for MEX:ACAD
Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ACAD has been successfully added to your 
